WallStSmart
IFRX

InflaRx N.V.

NASDAQ: IFRX · HEALTHCARE · BIOTECHNOLOGY

$2.43
-8.00% today

Updated 2026-06-05

Market cap
$271.02M
P/E ratio
P/S ratio
9,240.01x
EPS (TTM)
$-0.73
Dividend yield
52W range
$1 – $3
Volume
2.0M

InflaRx N.V. (IFRX) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-155,582.08%
Operating margin
-164,525.50%
ROE
-116.20%
ROA
-39.10%
Debt/equity
0.02x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2015$0.00$-4.92M
2016$0.00$-8.94M
2017$231000.00$-24.24M-29.62%-8,417.75%-10,492.64%
2018$0.00$-29.82M
2019$0.00$-53.25M
2020$0.00$-33.98M
2021$0.00$-45.63M
2022$0.00$-29.48M
2023$63089.00$-42.67M-743.67%-70,685.63%-67,630.69%
2024$165789.00$-46.06M-1,900.76%-31,911.39%-27,784.96%
2025$29331.00$-45.63M-24,677.94%-164,525.50%-155,582.08%

Frequently asked questions

What is InflaRx N.V.'s revenue?

InflaRx N.V.'s trailing twelve-month revenue is $29330.00. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is IFRX?

In its most recent fiscal year, IFRX ran a gross margin of -24,677.94%, an operating margin of -164,525.50%, and a net margin of -155,582.08%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does IFRX generate?

IFRX produced $-34.03M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is IFRX's balance sheet healthy?

IFRX holds $16.02M in cash and equivalents against — in long-term debt, on $41.54M of shareholder equity. That debt is best read against the cash flow the business throws off each year.